Benzatropine

Generic Name: Benzatropine

Brand Names: Cogentin

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅NO

CAS Number: 86-13-5

Unique Ingredient Identifier: 1NHL2J4X8K

Background: Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation...

Indication: 用于治疗帕金森病。也用于药物引起的锥体外系疾患，口服1小时起效，肌肉或静脉注射数分钟内起效，作用持续24小时。具有抗胆碱及抗组胺作用，并有轻度局部麻醉作用。

Associated Conditions: Parkinsonism

Associated Therapies: -

Clinical Trials

Schizophrenia Pharmacology: Version 2.0

KarXT (Cobenfy) was approved by the FDA for treating schizophrenia, marking the first new mechanism of action since 1954. Developed by Karuna Therapeutics, KarXT combines xanomeline and trospium to modulate brain circuits via a nondopaminergic mechanism. Clinical trials demonstrated significant improvements in symptoms, with KarXT not classified as an antipsychotic, differing from traditional D2R antagonists. Adverse events are mitigated by trospium's anticholinergic properties, and the drug has no boxed warnings. This approval introduces a novel neurotransmitter target for schizophrenia treatment.

Related Clinical Trials:

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

psychiatrictimes.com

3 months ago

KarXT: PDUFA Date Approaches for Potential Treatment for Schizophrenia

The FDA will respond to the New Drug Application for Bristol Myers Squibb and Karuna Therapeutic’s schizophrenia drug, KarXT, by September 26, 2024. KarXT, a muscarinic M1/M4 agonist, shows promise in reducing schizophrenia symptoms without metabolic, endocrine, or motor adverse effects, potentially positioning it as a first-line treatment alongside standard serotonin/dopamine antagonists.